If you have been strict on low FODMAP for six weeks and nothing has changed, the most useful thing to understand is that a null result is a real result. It is common, it is not a failure of willpower, and it narrows the field considerably. Somewhere between a quarter and half of people with IBS get no useful benefit from FODMAP restriction, and the response rates you were probably measured against are higher than the controlled evidence supports.
That gap matters, because people who do not respond tend to assume they did the diet wrong. Sometimes they did, and this guide covers those fixes first. But often the diet was executed perfectly and simply was not the right lever, either because something other than IBS is driving the symptoms or because the driver is a food component the diet never removed, or is not a food at all.
The short answer: stop, review, and do not add more weeks
If you have been genuinely strict for six weeks and your symptoms are unchanged, the next step is a review rather than a longer restriction. Check three things in order: whether the diet was executed the way the trials executed it, whether you are measuring "working" against a realistic bar, and whether something other than FODMAP-sensitive IBS is producing the symptoms. Only after those three does it make sense to move on to the alternatives that have their own randomised evidence.
The order matters because the fixable reasons are cheap to check and the unfixable ones are expensive to miss. Somebody who has been stacking three green portions inside two hours can rescue the diet in a week. Somebody with untreated bile acid diarrhoea can restrict fermentable carbohydrates for a year and get nowhere, because the mechanism has nothing to do with fermentation.
What "working" is supposed to look like
In the research, working means a drop of at least 50 points on the IBS Symptom Severity Score. That threshold is not arbitrary: the scale runs to 500, and the original validation study found that a change of 50 points reliably indicated genuine improvement rather than noise (Francis 1997). Most trials use that, or a simple yes-or-no question about whether you have had "adequate relief" of your symptoms over the past week.
Neither definition means symptom-free. In the low FODMAP arm of the sham-controlled trial, the mean severity score after four weeks was 173, which sits inside the mild-to-moderate band, not remission (Staudacher 2017). People who respond typically describe fewer bad days rather than none, less pain and bloating on the days they do have symptoms, and, the part they value most, more predictability about which days those will be.
This is worth saying plainly because a recurring theme in r/FODMAPS is people describing an honest 5 to 10 percent improvement and asking whether that counts. It does not. A thread about six weeks with little to no improvement is full of people trying to work out what success is supposed to feel like, and the replies from responders are consistent: they knew within one to two weeks, and the change was not subtle.
The success rate you were measured against was probably inflated
This is the part almost no page covers, and it changes how a null result should feel. We read the two pages currently ranking at the top for this question. One states that the diet improves symptoms in "3 out of 4" people, attributed to a numbered reference. The other gives a range of "50% to 86%" and averages it to "around 75%". Neither explains where the top of that range comes from.
It comes from a 2016 review whose abstract says "up to 86% of patients with IBS find improvement" (Nanayakkara 2016). Follow that back through the review's own table and the 86% is a composite symptom response rate from a study of 82 consecutive patients attending a London dietetic clinic, who filled in a questionnaire after their appointment (Staudacher 2011). That study was not randomised, not blinded, had no placebo or sham arm, and asked people to self-report improvement on a global scale after they had already been told which diet they were on. It is a useful clinical audit. It is not a success rate you should hold yourself against.
The other much-quoted figure, that most patients improve, traces to a prospective New Zealand study of 90 patients (de Roest 2013). Look at who was in it: every participant had already undergone hydrogen and methane breath testing, and 75.6% had fructose malabsorption. That is a population pre-selected for exactly the mechanism the diet targets, which is close to the best case rather than the average case. The study itself reports that symptom improvement was significantly associated with having fructose malabsorption.
Now look at the controlled numbers:
| Study | Design | Comparator | Result |
|---|---|---|---|
| Staudacher 2011 | Non-randomised clinic questionnaire | Standard NICE advice | 86% vs 49% composite symptom response |
| Halmos 2014 | Randomised crossover feeding study, 30 patients | Typical Australian diet | Significantly lower overall symptom scores on low FODMAP |
| Böhn 2015 | Randomised, single-blind, 67 completers | Traditional IBS dietary advice | 50% vs 46% achieved a 50-point severity drop (p = 0.72) |
| Eswaran 2016 | Randomised, 84 completers, IBS-D | Modified NICE advice | 52% vs 41% adequate relief (p = 0.31) |
| Staudacher 2017 | Randomised, blinded, sham diet | Sham restrictive diet | 57% vs 38% adequate relief (p = 0.051) |
Read as a set, those trials say something more modest than the marketing. The low FODMAP diet does beat a habitual diet: a network meta-analysis of 13 randomised trials in 944 patients ranked it first, with a relative risk of symptoms not improving of 0.67 against habitual diet (Black 2022). But against an active dietary comparator it has repeatedly failed to separate, and against a sham diet it missed significance on its primary endpoint. The authors of that network meta-analysis also note that most of the trials were run in secondary or tertiary care and none studied whether reintroduction and personalisation held up.
It is worth naming that the foundational efficacy trials, including the crossover feeding study, come from the research group at Monash University that developed the diet. That is verifiable from the papers' own author affiliations. We have not read every one of those papers' conflict-of-interest statements, so this is an observation about where the evidence originates, not a claim about anybody's disclosures.
None of this means the diet is useless. It means that if you did not respond, you are not an outlier against a 75 or 86 percent benchmark. You are in a group that the controlled evidence predicts will be large.
First, rule out the execution problems
Before concluding the diet failed, it is worth spending a week checking the things that most often undo it. These are quick to check and each one genuinely does convert some non-responders into responders.
Portion size and stacking. FODMAP content is dose dependent, not binary. Several servings that are individually fine can cross your threshold when they land inside a few hours, and drinks and snacks are the usual blind spot. A smoothie containing three different low-portion fruits is a worked example of the problem, not a safe breakfast. Our post on FODMAP stacking examples covers the mechanism and the common stacks in detail.
Hidden sources. Onion and garlic powder in stock, marinades, crisps and ready meals. Wheat as a thickener. Inulin and chicory root fibre added to "gut health" products, protein bars and some yoghurts. Sugar-free gum and mints. High fructose fruit juice concentrate in things that do not taste sweet.
Gluten-free is not low FODMAP. Many gluten-free products contain inulin, apple or pear concentrate, or honey. And low FODMAP is not gluten-free either: the target in wheat is fructans, not gluten, which is why small amounts of sourdough and some wheat-containing products are tolerated by many people.
Who taught you the diet. Guidelines consistently frame low FODMAP as a dietitian-delivered intervention, and the trials that produced the evidence used trained dietitians (Vasant 2021). That is not gatekeeping for its own sake: a dietitian catches the stacking, the hidden sources and the nutritional holes that self-led versions miss. That said, self-led is not automatically doomed. In a Belgian primary care trial, an app-delivered FODMAP-lowering diet outperformed a prescription antispasmodic, with 71% versus 61% responders at eight weeks; that trial was funded by the Belgian Health Care Knowledge Centre and the Rome Foundation Research Institute, both named in its title (Carbone 2022).
Whether the restriction was actually the restriction. The classic version cuts all FODMAP subgroups at once. A pilot randomised trial tested a simplified "FODMAP-simple" restriction phase removing only fructans and galacto-oligosaccharides, on the logic that those are the subgroups most likely to trigger symptoms (Singh 2025). It was a small, double-blind feasibility study rather than a definitive answer, but it is a reminder that "the diet" is not one fixed thing and that a less restrictive version is an active research question rather than a compromise.
If you have already weighed everything, used a reliable food list and spaced your portions, you can stop here. That was the fixable layer.
Was it the right six weeks?
Timing is its own confounder. The restriction phase is designed to run two to six weeks, and our post on how long to do the low FODMAP diet covers why that window and what changes at each point. What matters here is that a few things can make a good six weeks read as a bad one.
A course of antibiotics, a stomach bug, a bereavement, a new job, a cycle that landed badly, or an unusually bad sleep stretch can all keep symptoms high while the diet does its work underneath. If one of those overlapped most of your restriction phase, the null result is confounded rather than clean, and it may be worth a clean repeat after things settle. If nothing unusual happened, treat the result as real.
The other timing question is the reverse: some people improve, do not notice, and conclude it failed. If you started without a baseline measurement, the only comparison you have is memory, and memory of chronic symptoms is unreliable in both directions. Scoring your symptoms on the same scale weekly is the only way to see a 40-point drop that does not feel like anything. Logging portions, timing and symptoms as you go, in something like Clairop or a notebook, is mainly useful for this: it turns "I think it is about the same" into a line you can look at.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
The conditions that look like IBS and will never respond to FODMAP restriction
This is the most important section, and it is the one the diet blogs tend to hurry past. FODMAP restriction targets the osmotic and fermentative load reaching the small bowel and proximal colon. If your symptoms are driven by inflammation, bile acid excess, enzyme insufficiency, an immune reaction to gluten or an outlet problem, that lever is attached to nothing.
| Look-alike | What suggests it | Why FODMAPs will not help |
|---|---|---|
| Coeliac disease | Diarrhoea, weight loss, anaemia, family history; symptoms improve on gluten-free but not on low FODMAP with sourdough tolerated | It is an immune reaction to gluten, not fermentation. Testing requires you to be eating gluten |
| Bile acid diarrhoea | Urgent watery stools, often first thing or after meals, sometimes after gallbladder removal or ileal disease | Excess bile acid in the colon drives secretion and motility directly |
| Microscopic colitis | Chronic watery diarrhoea, often in people over 50, sometimes night-time stools | Inflammation of the colonic lining, diagnosed only on biopsy |
| Inflammatory bowel disease | Blood in the stool, night waking, weight loss, raised calprotectin | Active inflammation; needs treatment, not restriction |
| Pancreatic exocrine insufficiency | Pale, greasy, hard-to-flush stools, weight loss, history of pancreatic disease or alcohol | Fat maldigestion, a different mechanism entirely |
| Pelvic floor dysfunction in IBS-C | Straining, incomplete evacuation, needing to splint, laxatives not helping | An outlet problem. Nothing you remove upstream fixes coordination downstream |
| Post-infectious IBS | Symptoms that began after a documented gut infection or travel illness | May respond partly, but the trajectory and management differ |
A few of these deserve numbers.
Coeliac disease is common enough among people with IBS-type symptoms that both US and UK guidelines recommend serological screening. A meta-analysis of 36 studies in 15,256 people found that those meeting IBS criteria had roughly four times the odds of biopsy-proven coeliac disease compared with controls (Irvine 2017). The ACG guideline recommends serologic testing to rule out coeliac disease in people with IBS and diarrhoea (Lacy 2021). The practical trap is that the test needs gluten in your diet to be reliable. If you have spent months low FODMAP with wheat largely out, say so when you are tested, because it changes how the result should be read.
Bile acid diarrhoea is the big one for IBS-D non-responders and it is routinely missed. A systematic review of SeHCAT scanning in people diagnosed with IBS-D found that 32% had moderate bile acid malabsorption and 10% had severe malabsorption, with response rates to a bile acid binder of 80% and 96% respectively in those groups (Wedlake 2009). More recent reviews put the figure at 25 to 33% of people with functional diarrhoea and IBS-D (Marasco 2022). UK clinicians have argued for years that the diagnostic test is underused and that failure to diagnose is costly (Kurien 2018). If your main symptom is urgent watery diarrhoea and low FODMAP did nothing, this is worth naming to your doctor by name.
Microscopic colitis overlaps heavily with IBS in presentation. In a survey of people with a new histological diagnosis of microscopic colitis, 34% met Rome III criteria for IBS-type symptoms (Kane 2018). It is diagnosed on biopsy at colonoscopy, so it can only be found if someone looks.
Post-infectious IBS is worth knowing about because it reframes the question. Pooled across 45 studies, 10.1% of people developed IBS within 12 months of an episode of infectious enteritis, rising to 14.5% beyond 12 months, and the risk was 4.2 times higher than in people without enteritis. Where the cause was a protozoan or parasitic infection, 41.9% went on to develop IBS (Klem 2017). If your symptoms started after a specific illness or a trip, that history is clinically relevant and belongs in the conversation.
SIBO comes up constantly in non-responder threads, and the low FODMAP diet not working thread is a good example: the poster had been given the diet because of a SIBO diagnosis. It deserves a careful answer rather than an enthusiastic one. A joint European and American neurogastroenterology practice update concluded that after two decades the hypothesis that small intestinal bacterial overgrowth explains IBS symptoms in the absence of malabsorption remains unproven, and that the main unintended consequence has been widespread use of unvalidated breath tests and consequent antibiotic prescribing (Kashyap 2024). Our post on SIBO versus IBS symptoms goes through the testing problem and who genuinely has classical overgrowth.
The food components the diet never removed
If nothing structural is found, the next question is whether you are reacting to something that is not a FODMAP. The low FODMAP diet is narrowly targeted. It leaves fat, caffeine, alcohol, capsaicin, insoluble fibre, meal volume, meal timing and resistant starch completely untouched.
This is exactly why the head-to-head trials are so interesting. Traditional IBS dietary advice, as tested in Sweden, put the emphasis on how and when you eat rather than what: a regular meal pattern, avoiding large meals, and reducing fat, insoluble fibre, caffeine and gas-producing foods such as beans and cabbage. After four weeks, 50% of the low FODMAP group and 46% of the traditional advice group had achieved a 50-point severity drop, with no significant difference between them (Böhn 2015). The US trial against modified NICE advice found a similar pattern: 52% versus 41% for adequate relief, not significant, although low FODMAP did beat it specifically on abdominal pain, 51% versus 23% (Eswaran 2016).
Practically, that means someone who went low FODMAP but kept eating one enormous late meal a day with three coffees and a lot of fat may have removed the wrong variable. A UK consensus meeting on diet in IBS concluded there is a lack of evidence to suggest superiority of any one of these dietary approaches over another, and noted that traditional advice is more acceptable to patients (Rej 2022).
A note on the intolerances people raise most often in non-responder threads, because the evidence is thinner than the confidence:
- Dairy protein rather than lactose. Plausible, commonly reported, and the reason lactose-free milk can still cause symptoms. The volume, fat and protein all stay after the lactose is removed.
- Starch and sucrose. A real avenue. Reduced sucrase-isomaltase enzyme function has been studied as a reason for non-response, and starch- and sucrose-reduced diets have been trialled. The section below covers what the genetics actually showed.
- Histamine. Frequently suggested in threads and frequently sold as a protocol. The evidence base in IBS is weak and the tests offered commercially are not validated. It is not a reason to add another restriction on your own.
- Salicylates and amines. Also raised, also poorly supported. A scoping review of dietary interventions in IBS found the trial literature concentrated overwhelmingly on low FODMAP, traditional advice and gluten-free, which is a fair summary of where the evidence is and is not (Ohlsson 2026).
Adding a second or third restrictive diet on top of low FODMAP has a name in the literature now, diet stacking, and a review aimed at clinicians flags it as a growing risk requiring formal assessment, particularly for disordered eating (Melton 2025). Stacking diets is the single most common way a non-responder makes things worse.
When the driver is not the food at all
IBS is classified as a disorder of gut-brain interaction, and for a substantial group the dominant mechanism is visceral hypersensitivity: normal amounts of gas and normal gut movement are perceived as painful. No amount of subtracting fermentable carbohydrate changes how loudly the signal is read.
This is where the newest evidence is genuinely useful for non-responders. A 2026 prospective cohort followed 112 adults with Rome IV IBS through a three-phase low FODMAP diet over six months and looked at what predicted who improved. Higher baseline treatment credibility and expectancy predicted better symptom outcomes. Elevated gut-specific anxiety, psychological distress and negative illness perceptions predicted poorer ones (Manning 2026). Read carefully, that is not saying the symptoms are imagined. It is saying that the same gut, under high gut-focused anxiety, produces worse outcomes from the same diet, which is a treatable target in its own right.
The treatments aimed at that target have good randomised evidence. A network meta-analysis of 41 trials in 4,072 people found self-administered or minimal-contact cognitive behavioural therapy (relative risk of remaining symptomatic 0.61), face-to-face CBT (0.62) and gut-directed hypnotherapy (0.67) all effective (Black 2020). A later network meta-analysis looking specifically at abdominal pain across 42 trials found the same therapies on top (Goodoory 2024).
The single most relevant trial for someone who has just failed the diet compared gut-directed hypnotherapy against the low FODMAP diet directly. Across 74 participants, improvement in overall symptoms was equivalent between hypnotherapy, diet and the combination, with no difference across groups, and hypnotherapy produced better psychological outcomes (Peters 2016). That trial had no placebo arm, so the shared improvement cannot be fully attributed to either treatment, but it is the reason a dietitian or gastroenterologist may suggest a brain-gut route rather than another diet. Our post on whether gut-directed hypnotherapy works for IBS covers the evidence and the access problem in detail, and whether stress causes IBS flares covers the mechanism.
Can anything predict whether the diet will work for you?
Not yet, and the honest version of that answer is more useful than the confident one. A 2025 narrative review looked at every candidate predictor studied so far, including baseline symptom severity, psychological factors, hydrogen breath test results, volatile organic compounds in stool and gut microbiota profiles. It concluded that clinical and psychological measures show the most immediate potential because they are accessible and already measurable, while biological markers including breath testing, metabolomics and microbiome analysis need further validation before they can guide practice (Manning 2025).
Three specific lines are worth knowing about, because you will see them sold.
Microbiome tests. A study of 61 patients with IBS did find that faecal bacterial profiles discriminated responders from non-responders to a low FODMAP diet, both before and after the intervention, with bacterial abundance tending to be higher in non-responders (Bennet 2018). That analysis used a commercial dysbiosis test, and we have not read the study's funding statement, so we are not claiming anything about who paid for it. What we can say is that one modelling study in 61 people is not a validated clinical test, and the direct-to-consumer gut microbiome kits being sold today are not this test and have not been shown to predict anything about your diet response.
Metabolomics. A Swedish group ran a double-blind crossover study provoking people with IBS with FODMAPs, gluten or placebo, then tried to predict who reacted using faecal microbiota, short chain fatty acids and untargeted plasma metabolomics. Out of 864 clustering models, only two showed significant associations, and those had no link to baseline clinical measures. Their conclusion was that differential responses to FODMAP or gluten exposure could not be predicted (Nordin 2024). That is a negative result, and it deserves to be as well known as the positive ones.
Sucrase-isomaltase genetics. This one is a good lesson in reading past the headline. A 2020 research letter in Gut reported reduced efficacy of the low FODMAP diet in people with IBS-D carrying hypomorphic variants of the sucrase-isomaltase gene (Zheng 2020). The specific percentages that circulate on health sites come from secondary reporting of that letter; its abstract is not indexed, so we cannot verify those figures here and will not repeat them. What we can report is what a 2026 study found when it went looking again. Seventy-two Australian patients with IBS who had been educated on the FODMAP diet a mean of 7.1 years earlier were genotyped: 54% carried at least one hypomorphic variant, and on adjusted analysis there was no difference between genotype groups in initial response to the diet or in long-term symptom control (Silva 2026). One small cross-sectional study does not overturn a finding either, but it means the genetic explanation for non-response is contested, not established.
A worked example: three people, three kinds of non-response
All three did six strict weeks and got nothing. The useful part is how differently the next step should look.
Person one, IBS-M, weighed everything. Reviewing her log with a dietitian, three things surfaced: a daily smoothie with three fruits in it, garlic-infused oil used at every meal, and a protein powder she had assumed was fine from the ingredient list. None of those is a diet failure so much as a dose problem. She spaced fruit to one portion at a time, dropped the powder for a fortnight, and reduced the oil. Two weeks later her severity score was 60 points lower. That is the stacking pattern, and it is the most common recoverable one.
Person two, IBS-D, urgent watery stools, often within twenty minutes of eating. Execution was perfect and the log proved it. What had never been done was a SeHCAT scan or a serum bile acid test, and coeliac serology had been taken after she had already been gluten-light for three months. Both of those are conversations with a doctor, not diet changes, and both were reasonable to raise given her dominant symptom. Her next step was a GP appointment with a one-page summary of what she had tried and what had not been tested, not another elimination.
Person three, IBS-C with constant pain and bloating. The diet did nothing, but the log showed something else: symptom intensity tracked her workload almost perfectly and had done for two years, and she described checking her abdomen several times a day and cancelling plans pre-emptively. Her gut-specific anxiety score would sit high on any measure. The evidence-based next step there is a brain-gut behavioural therapy, not a second diet, and possibly an assessment for a defecatory disorder given the constipation.
None of those three did the diet wrong. They had three different problems wearing the same symptoms.
What to do next, in order
- Get a proper review rather than extending restriction. Six strict weeks with no change is a complete data point.
- Bring numbers, not adjectives. A weekly severity score, stool form, and what you actually ate is far more use to a clinician than "still bad". Our guide to keeping a food diary for IBS covers what to record and what to leave out.
- Ask what has been excluded and what has not. Specifically: coeliac serology while eating gluten, faecal calprotectin, full blood count and ferritin, and, if your main symptom is watery diarrhoea, whether bile acid diarrhoea has been tested for. If you are unsure whether you need a specialist, our post on whether to see a gastroenterologist for IBS walks through the referral decision.
- Reintroduce. Even after a null result, structured reintroduction matters, because staying restricted for no benefit is all cost. Our guides to reintroducing foods and reintroduction order cover the mechanics.
- Consider the non-FODMAP dietary levers. Meal pattern, meal size, fat, caffeine, alcohol and fibre type. These are what traditional dietary advice targets, and it matched low FODMAP head to head.
- Ask about the treatments that are not diets. Brain-gut behavioural therapies, and medicines chosen by symptom subtype. Both UK and US guidelines set these out, and IBS management in practice often does not keep pace with them (Vasant 2021, Lacy 2021). We are not going to tell you which medicine or dose; that is your doctor's call.
The cost of staying on a diet that is not working
This part is easy to skip and should not be. Four weeks of low FODMAP measurably changes what you eat: analysis of 130 people from two randomised trials found effects on nutrient intake and reduced diet diversity relative to controls, and the authors flagged nutritional risk as a reason the diet needs dietetic supervision (Staudacher 2020). A major review of dietary management in IBS goes further, noting the burden of restriction on food-related quality of life and the concern about restrictive whole-diet interventions and eating disorder risk (Whelan 2024).
Even the researchers most associated with the diet are explicit that it was never designed as a permanent state. The full programme is restriction, then reintroduction, then personalisation, and they have proposed a lighter "FODMAP-gentle" version precisely because indefinite full restriction is the wrong endpoint (Halmos 2019).
The risk is not theoretical, and the direction of travel in non-responder threads is recognisable: the diet does not work, so the list of removed foods grows, and eating becomes a source of dread rather than fuel. Our post on whether the low FODMAP diet can cause an eating disorder covers the risk factors and what the warning signs look like. If eating has started to feel frightening, that is worth raising with a clinician on its own, separately from the gut symptoms.
Myths about the low FODMAP diet not working
"It works for 75% of people, so I must have done it wrong." The controlled trials do not support that number. Against a sham diet the difference was 57% versus 38% and missed significance (Staudacher 2017), and against active dietary comparators it has repeatedly tied (Böhn 2015, Eswaran 2016).
"If six weeks did not work, twelve might." No trial supports extending restriction to rescue a non-response, and the restriction phase in the evidence base is typically four weeks. Longer restriction increases the nutritional and psychological cost without a matching chance of benefit.
"Non-response means I need to cut more foods." More often it means the target was wrong. Stacking restrictive diets is now recognised in the clinical literature as a risk that needs formal assessment (Melton 2025).
"A gut microbiome test will tell me why." One research study found faecal bacterial profiles discriminated responders from non-responders (Bennet 2018), but a 2025 review of predictors concluded microbiome and metabolomic markers are not ready for routine use (Manning 2025), and a crossover provocation study could not predict who reacted at all (Nordin 2024).
"Non-response proves it is all in my head." No. It means fermentable carbohydrate was not the dominant mechanism for you. That could be bile acids, inflammation, enzymes, an outlet problem, fat or caffeine, or gut-brain signalling. Only one of those has anything to do with whether you believe your symptoms.
"If FODMAPs are not the problem I should stop tracking." The opposite, usually. A clean log is what lets a clinician see that your urgency is post-prandial and watery rather than food-specific, or that symptoms track workload rather than meals. Our guide to finding out what triggers your IBS covers how to make a diary produce answers rather than suspects.
When to see a doctor promptly
Some findings mean the question is no longer about diet at all. See a doctor promptly if you have any of the following:
- Blood in your stool, or black tarry stools
- Unexplained weight loss
- Fever alongside gut symptoms
- Symptoms that wake you from sleep
- Anaemia, or fatigue with a low ferritin or haemoglobin
- New bowel symptoms starting after age 50
- A family history of bowel cancer, coeliac disease or inflammatory bowel disease
- A sudden change in your usual pattern that persists for more than a few weeks
- Pale, greasy stools that are hard to flush
- Persistent vomiting or difficulty swallowing
None of these are typical of IBS, and none of them should be managed by adjusting your diet while you wait. Also worth a prompt appointment: symptoms that began after a specific gut infection or a trip abroad, because that history changes the investigation (Klem 2017).
If your mental health has deteriorated alongside the gut symptoms, raise that too. Up to a third of people with IBS also experience anxiety or depression, and the psychological comorbidity is more predictive of long-term quality of life than the gut symptoms themselves (Staudacher 2023). That is an argument for treating it, not for ignoring the gut.
The short version
A null result on the low FODMAP diet is common, and the benchmark you measured yourself against was probably built from uncontrolled studies. Before concluding anything, check the fixable layer: portions, stacking, hidden sources, and whether you had a baseline to compare against. Then check whether you were ever the right candidate, because coeliac disease, bile acid diarrhoea, microscopic colitis, IBD, pancreatic insufficiency and pelvic floor dysfunction produce the same symptoms through mechanisms FODMAP restriction cannot touch.
If nothing structural turns up, the next levers are the ones the diet left alone: meal pattern and size, fat, caffeine, alcohol and fibre type, all of which traditional dietary advice targets and which matched low FODMAP in head-to-head trials. And if your symptoms track stress, anxiety or hypervigilance more than they track meals, the brain-gut therapies have randomised evidence behind them and one trial found hypnotherapy performed comparably to the diet itself.
What is not a good next step is another six weeks, another elimination, or a commercial test promising to explain your microbiome. Reintroduce, get the gaps in your workup filled, and spend your effort on the lever that is actually attached to your mechanism.
